Pharmacogenomic Effect/ADR for Succinylcholine (DBSNPE007183)

Identifier
DBSNPE007183
Drug
Succinylcholine (DB00202)
Interacting Gene/Enzyme
Ryanodine receptor 1
Gene Name
RYR1
UniProt ID
P21817
Defining Change(s)
c.103T>Crs193922747
c.487C>Trs118192161
c.488G>Trs193922753
c.742G>Ars1801086
c.742G>Crs1801086
c.1021G>Ars121918592
c.1209C>Grs118192116
c.1565A>Crs118192162
c.1589G>ANot Available
c.1654C>Trs193922770
c.1840C>Trs118192172
c.1841G>Trs193922772
c.6487C>Trs118192175
c.6488G>Ars118192163
c.6502G>Ars118192176
c.6617C>Grs118192177
c.6617C>Trs118192177
c.7007G>ANot Available
c.7048G>Ars193922802
c.7124G>Crs193922807
c.7282G>Ars193922809
c.7300G>Ars121918593
c.7304G>Ars28933396
c.7360C>Trs193922816
c.7361G>Ars118192122
c.7372C>Trs28933397
c.7373G>Ars121918594
c.7522C>Trs118192178
c.7523G>ANot Available
c.14387A>Grs118192167
c.14477C>Trs121918595
c.14497C>TNot Available
c.14512C>Grs193922878
c.14582G>Ars63749869
c.14693T>Crs118192170
Allele Name
Not Available
Genotype(s)
Not Available
Type(s)
ADR Inferred
Groups
Malignant hyperthermia vulnerability
Description
Malignant hyperthermia.
References
  1. Anectine® (Succinylcholine Chloride Injection)[package insert]. Princeton, New Jersey: Sandoz Inc.; 2012. [Link]